Research Advance on the Immune Escape of Acute Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1429-1432, 2020.
Article
em Zh
| WPRIM
| ID: wpr-827099
Biblioteca responsável:
WPRO
ABSTRACT
Acute myeloid leukemia (AML) is a kind of malignant hematological disease with high mortality. Patients 5-year survival rate is less than 25% and that of elderly patients is lower than 10%. Although the standardized chemotherapy or hematopoetic stem cell transplantation can significantly improve the therapeutic efficacy for AML, but disease recurrence is still a difficult problem in most patients. Chemotherapy combined with immunotherapy has been regarded as the most promising treatment for AML in recent years, but immunotherapy is prone to immune escape, which has become an important factor affecting the therapeutic efficacy. Therefore, understanding the mechanism of immune escape of AML and taking corresponding measures in time to improve the therapeutic effect and reduce the recurrence of AML are of great significance. In this review, the important cells that cause immune escape, such as myeloid-derived suppressor cells (MDSC), natural killer cells (NK), and cell surface inhibitory receptor PD-1 (programmed death 1), which mediate immune escape of AML cells are summarized, so as to provide valuable reference for research to improve the effect of AML immunotherapy.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Células Matadoras Naturais
/
Leucemia Mieloide Aguda
/
Transplante de Células-Tronco Hematopoéticas
/
Transplante de Células-Tronco
/
Imunoterapia
Limite:
Aged
/
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2020
Tipo de documento:
Article